person · Reporting owner
Georgantas Robert William III
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIODESIX INCBDSX · Entity 6053 | Chief Scientific Officer | November 21, 2022 | November 21, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIODESIX INC
Report date November 21, 2022 · Filed November 21, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 38,114 |
Reported balance
After 2022-11-21 transaction · row 1
1 source rowRow 1 · 2022-11-21 · Grant · Acquired 12,000 · Balance 38,114 |
| Common StockSEC Table I · non-derivative | IndirectBy UGMA Account | 100 |
Reported balance
Holding disclosure · report date 2022-11-21 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 100 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 21, 2022 Filed Nov 21, 2022 23:02 UTC | BIODESIX INC BDSX · Entity 6053 | GrantCommon Stock | 12,000 | $1.15 | $13,800.00 |
DisclosureSEC source: 0001140361-22-042595 · form4.xml · nonDerivative · entry 1 Georgantas Robert William III · CIK 0001827728 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,114 Read SEC document |
| November 10, 2022 Filed Nov 11, 2022 02:02 UTC | BIODESIX INC BDSX · Entity 6053 | SaleCommon Stock | 785 | $1.02 | $798.74 |
DisclosureSEC source: 0001140361-22-041081 · form4.xml · nonDerivative · entry 3 Georgantas Robert William III · CIK 0001827728 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,114 F4 · kind: These Shares were sold automatically to cover taxes upon the vesting of RSUs. F6 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.00 to $1.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 09, 2022 Filed Nov 11, 2022 02:02 UTC | BIODESIX INC BDSX · Entity 6053 | SaleCommon Stock | 991 | $1.04 | $1,032.42 |
DisclosureSEC source: 0001140361-22-041081 · form4.xml · nonDerivative · entry 2 Georgantas Robert William III · CIK 0001827728 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,899 F4 · kind: These Shares were sold automatically to cover taxes upon the vesting of RSUs. F5 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.00 to $1.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 08, 2022 Filed Nov 11, 2022 02:02 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionRestricted Stock Units · Derivative | 3,676 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-041081 · form4.xml · derivative · entry 6 Georgantas Robert William III · CIK 0001827728 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,026 Underlying: Common Stock · 3,676 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock (each, a "Share"). F3 · derivative.exercise_date: These RSUs vest in a series of six successive quarterly installments from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date. F3 · derivative.expiration_date: These RSUs vest in a series of six successive quarterly installments from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date. Read SEC document |
| November 08, 2022 Filed Nov 11, 2022 02:02 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionRestricted Stock Units · Derivative | 1,970 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-041081 · form4.xml · derivative · entry 5 Georgantas Robert William III · CIK 0001827728 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,624 Underlying: Common Stock · 1,970 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock (each, a "Share"). F2 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date. F2 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date. Read SEC document |
| November 08, 2022 Filed Nov 11, 2022 02:02 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionCommon Stock | 5,646 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-22-041081 · form4.xml · nonDerivative · entry 1 Georgantas Robert William III · CIK 0001827728 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,890 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock (each, a "Share"). Read SEC document |
| August 09, 2022 Filed Aug 10, 2022 22:54 UTC | BIODESIX INC BDSX · Entity 6053 | SaleCommon Stock | 1,686 | $2.53 | $4,262.55 |
DisclosureSEC source: 0001140361-22-029135 · form4.xml · nonDerivative · entry 2 Georgantas Robert William III · CIK 0001827728 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,244 F4 · kind: These Shares were sold automatically to cover taxes upon the vesting of RSUs. F5 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $2.38 to $2.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 08, 2022 Filed Aug 10, 2022 22:54 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionRestricted Stock Units · Derivative | 3,675 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-029135 · form4.xml · derivative · entry 5 Georgantas Robert William III · CIK 0001827728 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,702 Underlying: Common Stock · 3,675 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock (each, a "Share"). F3 · derivative.exercise_date: These RSUs vest in a series of six successive quarterly installments from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date. F3 · derivative.expiration_date: These RSUs vest in a series of six successive quarterly installments from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date. Read SEC document |
| August 08, 2022 Filed Aug 10, 2022 22:54 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionRestricted Stock Units · Derivative | 1,972 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-029135 · form4.xml · derivative · entry 4 Georgantas Robert William III · CIK 0001827728 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,594 Underlying: Common Stock · 1,972 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock (each, a "Share"). F2 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date. F2 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date. Read SEC document |
| August 08, 2022 Filed Aug 10, 2022 22:54 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionCommon Stock | 5,647 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-22-029135 · form4.xml · nonDerivative · entry 1 Georgantas Robert William III · CIK 0001827728 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,930 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock (each, a "Share"). Read SEC document |
| May 10, 2022 Filed May 12, 2022 01:42 UTC | BIODESIX INC BDSX · Entity 6053 | SaleCommon Stock | 2,004 | $1.83 | $3,667.32 |
DisclosureSEC source: 0001140361-22-018734 · form4.xml · nonDerivative · entry 2 Georgantas Robert William III · CIK 0001827728 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,283 F4 · kind: These Shares were sold automatically to cover taxes upon the vesting of RSUs. F5 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.73 to $1.945, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 09, 2022 Filed May 12, 2022 01:42 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionRestricted Stock Units · Derivative | 3,676 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-018734 · form4.xml · derivative · entry 5 Georgantas Robert William III · CIK 0001827728 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,377 Underlying: Common Stock · 3,676 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock (each, a "Share"). F3 · derivative.exercise_date: These RSUs vest in a series of six successive quarterly installments from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date. F3 · derivative.expiration_date: These RSUs vest in a series of six successive quarterly installments from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date. Read SEC document |
| May 09, 2022 Filed May 12, 2022 01:42 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionRestricted Stock Units · Derivative | 1,971 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-018734 · form4.xml · derivative · entry 4 Georgantas Robert William III · CIK 0001827728 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,566 Underlying: Common Stock · 1,971 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock (each, a "Share"). F2 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date. F2 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date. Read SEC document |
| May 09, 2022 Filed May 12, 2022 01:42 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionCommon Stock | 5,647 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-22-018734 · form4.xml · nonDerivative · entry 1 Georgantas Robert William III · CIK 0001827728 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,287 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock (each, a "Share"). F6 · balance_after: Includes 1,262 and 2,604 Shares acquired under the BDSX stock purchase plan on August 31, 2021 and February 28, 2022, respectively. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 21:56 UTC | BIODESIX INC BDSX · Entity 6053 | GrantStock Options (Right to buy) · Derivative | 22,722 | $0.00 Strike: $2.29 | $0.00 |
DisclosureSEC source: 0001567619-22-006924 · doc1.xml · derivative · entry 1 Georgantas Robert William III · CIK 0001827728 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,722 Underlying: Common Stock · 22,722 shares Expires 2032-03-09 Read SEC document |
| March 10, 2022 Filed Mar 18, 2022 20:53 UTC | BIODESIX INC BDSX · Entity 6053 | GrantStock Options (Right to buy) · Derivative | 2,842 | $0.00 Strike: $0.77 | $0.00 |
DisclosureSEC source: 0001567619-22-007219 · doc1.xml · derivative · entry 2 Georgantas Robert William III · CIK 0001827728 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,685 Underlying: Common Stock · 2,842 shares Expires 2030-04-14 F1 · shares: On April 15, 2020, the Reporting Person was granted an option to purchase 5,685 shares (as-adjusted for the 0.1684664-for-1 reverse stock split effected on October 19, 2020), the vesting of which was subject to the Issuer's satisfaction of certain performance criteria for each of the 2020 and 2021 fiscal years. F3 · shares: On March 10, 2022, the Compensation Committee confirmed the performance criteria were met for fiscal year 2021, resulting in the vesting of 2,842 shares underlying the option. F1 · derivative.exercise_date: On April 15, 2020, the Reporting Person was granted an option to purchase 5,685 shares (as-adjusted for the 0.1684664-for-1 reverse stock split effected on October 19, 2020), the vesting of which was subject to the Issuer's satisfaction of certain performance criteria for each of the 2020 and 2021 fiscal years. F3 · derivative.exercise_date: On March 10, 2022, the Compensation Committee confirmed the performance criteria were met for fiscal year 2021, resulting in the vesting of 2,842 shares underlying the option. Read SEC document |
| February 08, 2022 Filed Feb 11, 2022 00:08 UTC | BIODESIX INC BDSX · Entity 6053 | GrantRestricted Stock Units · Derivative | 22,053 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-004585 · form4.xml · derivative · entry 2 Georgantas Robert William III · CIK 0001827728 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,053 Underlying: Common Stock · 22,053 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: These RSUs vest in a series of six successive quarterly installments from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date. F3 · derivative.expiration_date: These RSUs vest in a series of six successive quarterly installments from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date. Read SEC document |
| February 08, 2022 Filed Feb 11, 2022 00:08 UTC | BIODESIX INC BDSX · Entity 6053 | GrantRestricted Stock Units · Derivative | 31,537 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-004585 · form4.xml · derivative · entry 1 Georgantas Robert William III · CIK 0001827728 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,537 Underlying: Common Stock · 31,537 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date. F2 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 20:15 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionStock Option (Right to buy) · Derivative | 10,219 | $0.00 Strike: $0.77 | $0.00 |
DisclosureSEC source: 0001140361-21-011991 · form4.xml · derivative · entry 3 Georgantas Robert William III · CIK 0001827728 · Director · SVP, Rsrch & Trans'l Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,262 Underlying: Common Stock · 10,219 shares Expires 2030-04-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: This Form 4 corrects the exercise price previously reported as $0.78 on the Form 3 filed on October 27, 2020. F1 · derivative.exercise_date: This option vests 20% on January 1, 2021, and the remaining 80% in 48 successive, equal monthly installments measured from January 1, 2021. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 20:15 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionCommon Stock | 10,219 | $0.77 | $7,868.63 |
DisclosureSEC source: 0001140361-21-011991 · form4.xml · nonDerivative · entry 1 Georgantas Robert William III · CIK 0001827728 · Director · SVP, Rsrch & Trans'l Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,774 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 23, 2021 Filed Mar 18, 2022 20:53 UTC | BIODESIX INC BDSX · Entity 6053 | GrantStock Options (Right to buy) · Derivative | 2,843 | $0.00 Strike: $0.77 | $0.00 |
DisclosureSEC source: 0001567619-22-007219 · doc1.xml · derivative · entry 1 Georgantas Robert William III · CIK 0001827728 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,843 Underlying: Common Stock · 2,843 shares Expires 2030-04-14 F1 · shares: On April 15, 2020, the Reporting Person was granted an option to purchase 5,685 shares (as-adjusted for the 0.1684664-for-1 reverse stock split effected on October 19, 2020), the vesting of which was subject to the Issuer's satisfaction of certain performance criteria for each of the 2020 and 2021 fiscal years. F2 · shares: On February 23, 2021, the Compensation Committee of the Issuer's board of directors (the "Compensation Committee") confirmed the performance criteria were met for fiscal year 2020, resulting in the vesting of 2,843 shares underlying the option. F1 · derivative.exercise_date: On April 15, 2020, the Reporting Person was granted an option to purchase 5,685 shares (as-adjusted for the 0.1684664-for-1 reverse stock split effected on October 19, 2020), the vesting of which was subject to the Issuer's satisfaction of certain performance criteria for each of the 2020 and 2021 fiscal years. F2 · derivative.exercise_date: On February 23, 2021, the Compensation Committee of the Issuer's board of directors (the "Compensation Committee") confirmed the performance criteria were met for fiscal year 2020, resulting in the vesting of 2,843 shares underlying the option. Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 23:27 UTC | BIODESIX INC BDSX · Entity 6053 | PurchaseCommon Stock | 100 | $18.00 | $1,800.00 |
DisclosureSEC source: 0001209191-20-056755 · doc4.xml · nonDerivative · entry 2 Georgantas Robert William III · CIK 0001827728 · Director · SVP, Rsrch & Trans'l Science 10b5-1 filing: Not disclosed Ownership: Indirect · By UGMA Account Disclosed balance after: 100 Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 23:27 UTC | BIODESIX INC BDSX · Entity 6053 | PurchaseCommon Stock | 555 | $18.00 | $9,990.00 |
DisclosureSEC source: 0001209191-20-056755 · doc4.xml · nonDerivative · entry 1 Georgantas Robert William III · CIK 0001827728 · Director · SVP, Rsrch & Trans'l Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 555 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.